P76.36 A Phase 2 Study of Anlotinib Combined with Pemetrexed-Platinum (PP) as Second-Line Treatment in EGFR-Positive Non-Small Cell Lung Cancer (NSCLC)
2021
Keywords:
-
Correction
-
Source
-
Cite
-
Save
0
References
0
Citations
NaN
KQI